PEGylated recombinant human interferon-ω as a long-acting antiviral agent: Structure, antiviral activity and pharmacokinetics

Antiviral Research

Volumn 108, Issue 1, 2014, Pages 142-147

  Yu, Weili ^a,c   Yu, Changming ^b   Wu, Ling ^a,c   Fang, Ting ^b   Qiu, Rui ^a   Zhang, Jinlong ^b   Yu, Ting ^b   Fu, Ling ^b   Chen, Wei ^b   Hu, Tao ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Antiviral agent; Interferon ; PEGylation; Pharmacokinetics

Indexed keywords

ANTIVIRUS AGENT; LYSINE; MACROGOL; PEGYLATED RECOMBINANT HUMAN INTERFERON OMEGA; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG; INTERFERON; MACROGOL DERIVATIVE;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; MALE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; MOLECULAR WEIGHT; RABBIT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIVIRAL AGENTS; INTERFERONS; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903643701     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.06.003     Document Type: Article

References (17)

1. J. Bekisz, H. Schmeisser, J. Hernandez, N.D. Goldman, and K.C. Zoon Human interferons alpha, beta and omega Growth Factors 22 2004 243 251 (Pubitemid 40123402)
2. A. Boulestin, N. Kamar, K. Sandres-Saune, L. Alric, J.P. Vinel, L. Rostaing, and J. Izopet Pegylation of IFN-α and antiviral activity J. Interfer. Cytokine Res. 26 2006 849 853
3. V.E. Buckwold, W. Lang, C. Scribner, D. Blanchett, T. Alessi, and P. Langecker Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human ω-interferon produced from CHO-SS cells Basic Clin. Pharmacol. Toxicol. 99 2006 62 70 (Pubitemid 44034397)
4. V.E. Buckwold, J. Wei, Z. Huang, C. Huang, A. Nalca, J. Wells, J. Russell, B. Collins, R. Ptak, W. Lang, C. Scribner, D. Blanchett, T. Alessi, and P. Langecker Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses Antiviral Res. 73 2007 118 125 (Pubitemid 46138065)
5. D.J. Capon, H.M. Shepard, and D.V. Goeddel Two distinct families of human and bovine interferon-α genes are coordinately expressed and encode functional polypeptides Mol. Cell Biol. 5 1985 768 779 (Pubitemid 15101187)
6. R.B. Greenwald, Y.H. Choe, J. McGuire, and C.D. Conover Effective drug delivery by PEGylated drug conjugates Adv. Drug Del. Rev. 55 2003 217 250 (Pubitemid 36135917)
7. T. Hu, B.N. Manjula, D. Li, M. Brenowitz, and S.A. Acharya Influence of intramolecular cross-links on the molecular, structural and functional properties of PEGylated hemoglobin Biochem. J. 402 2007 143 151
8. J.G. Julander, J.D. Morrey, L.M. Blatt, K. Shafer, and R.W. Sidwell Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model Antiviral Res. 73 2007 140 146 (Pubitemid 46135771)
9. J. Li, B. Li, J. Zhang, L. Hou, C. Yu, L. Fu, X. Song, T. Yu, J. Zhang, J. Ren, C. Xu, and W. Chen Preparation of CHO cell-derived rhIFN-ω-Fc with improved pharmacokinetics Antiviral Res. 89 2011 199 203
10. K.L. Lindsay, C. Trepo, T. Heintges, M.L. Shiffman, S.C. Gordon, J.C. Hoefs, E.R. Schiff, Z.D. Goodman, M. Laughlin, R. Yao, and J.K. Albrecht A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403 (Pubitemid 32702353)
11. R. Liu, D. Li, J. Wang, R. Qiu, Q. Lin, G. Zhang, G. Ma, Z. Su, and T. Hu Preparation, characterization and in vitro bioactivity of N-terminally PEGylated staphylokinase dimers Process Biochem. 47 2012 41 46
12. S. Liu, L. Sun, J. Wang, G. Ma, Z. Su, and T. Hu Mono-PEGylation of ribonuclease A: high PEGylation efficiency by thiolation with small molecular weight reagent Process Biochem. 47 2012 1364 1370
13. Q. Mu, T. Hu, and J. Yu Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation PLoS One 8 2013 e68559
14. D. Olagnier, F.E.M. Scholte, C. Chiang, I.C. Albulescu, C. Nichols, Z. He, R. Lin, E.J. Snijder, M.J. van Hemert, and J. Hiscotta Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response J. Virol. 88 2014 4180 4194
15. C. Xu, X. Song, L. Fu, D. Dong, S. Wu, G. Li, S. Yi, T. Yu, R. Yu, L. Hou, and W. Chen Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009A (H1N1) Influenza virus Viral Immunol. 24 2011 369 374
16. X. Xue, D. Li, J. Yu, G. Ma, Z. Su, and T. Hu Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally mono-PEGylated staphylokinase Biomacromolecules 14 2013 331 341
17. S. Zeuzem, S.V. Feinman, J. Rasenack, E.J. Heathcote, M.Y. Lai, E. Gane, J. O'Grady, J. Reichen, M. Diago, A. Lin, J. Hoffman, and M.J. Brunda Peginterferon alfa-2a in patients with chronic hepatitis C N. Engl. J. Med. 343 2000 1666 1672